Status and phase
Conditions
Treatments
About
The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Additional Inclusion/Exclusion criteria may apply per protocol
Primary purpose
Allocation
Interventional model
Masking
75 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal